Contact
searchSearch
HMP Global
Login

Advertisement

ADVERTISEMENT

Column

Clinical Pathways GPS
Impact of Quality of Life on Clinical Pathways
08/02/2016
Jill Cantelmo, DPhil, MSc
Seth Gordon, MBA
Richard G Stefanacci, DO, MGH, MBA, AGSF, CMD—Column Editor
For clinical pathway developers seeking to define the value of different treatments, quality-of-life (QOL) measures offer a means of capturing the factors that most define value to the patient and their caregivers....
For clinical pathway developers seeking to define the value of different treatments, quality-of-life (QOL) measures offer a means of capturing the factors that most define value to the patient and their caregivers....
For...
08/02/2016
Journal of Clinical Pathways
Editor's Page
Can Value Frameworks Effect Real Change in Health Care?
08/02/2016
Winston Wong, PharmD, Editor-in-Chief
The concept of value in health care has become increasingly important, and this is unlikely to change any time soon. Health care reforms have been proposed in order to slow the increase in health care costs while...
The concept of value in health care has become increasingly important, and this is unlikely to change any time soon. Health care reforms have been proposed in order to slow the increase in health care costs while...
The...
08/02/2016
Journal of Clinical Pathways

Advertisement

Pharma Insights
Could the Lack of an Efficient and Affordable Diagnostic Pathway Limit Market Access for New Alzheimer`s Treatments?
06/20/2016
Rick Lifsitz, MBA
Larry Blandford, PharmD—Column Editor
The promise in the coming years of a novel therapeutic to slow the progression of the debilitating effects of Alzheimer’s disease (AD) is exciting and represents a monumental step forward in treating patients with...
The promise in the coming years of a novel therapeutic to slow the progression of the debilitating effects of Alzheimer’s disease (AD) is exciting and represents a monumental step forward in treating patients with...
The...
06/20/2016
Journal of Clinical Pathways
Clinical Pathways GPS
Beyond Medication Class: How Specific Should the Clinical Pathway Get?
06/20/2016
Richard G Stefanacci, DO, MGH, MBA, AGSF, CMD–Column Editor
Taha Khan, PharmD, RPh
Aspects of a medication beyond the chemical composition can have an impact on patient outcomes. Consideration of these aspects when developing clinical pathways may result in particular formulations or delivery...
Aspects of a medication beyond the chemical composition can have an impact on patient outcomes. Consideration of these aspects when developing clinical pathways may result in particular formulations or delivery...
...
06/20/2016
Journal of Clinical Pathways
Editor's Page
Pathways for Improving Quality of Life
06/20/2016
Winston Wong, PharmD, Editor-in-Chief
As early detection of cancers and improved treatments continue to improve outcomes for patients with cancer, care providers have been able to increase their focus on the quality of life for patients with cancer who...
As early detection of cancers and improved treatments continue to improve outcomes for patients with cancer, care providers have been able to increase their focus on the quality of life for patients with cancer who...
As...
06/20/2016
Journal of Clinical Pathways

Advertisement

Counterpoint
Keeping Cures on the Shelf
05/06/2016
George Dahlman
Regulatory action has been taken to address the problem of drug shortages for pediatric cancer patients. However, there is still more work to be done. During 2010 and 2011, the news headlines were filled with...
Regulatory action has been taken to address the problem of drug shortages for pediatric cancer patients. However, there is still more work to be done. During 2010 and 2011, the news headlines were filled with...
...
05/06/2016
Journal of Clinical Pathways
Viewpoint
Chemotherapy Shortages: When is Enough, Enough?
05/06/2016
Yoram Unguru, MD, MS, MA
Shortages of life-saving chemotherapy agents and supportive care drugs have presented physicians treating children with cancer with difficult decisions regarding drug allocation and prioritization. Guidelines...
Shortages of life-saving chemotherapy agents and supportive care drugs have presented physicians treating children with cancer with difficult decisions regarding drug allocation and prioritization. Guidelines...
...
05/06/2016
Journal of Clinical Pathways
Pharma Insights
Companion Diagnostics and Complementary Diagnostics in Clinical Practice: Better Medicine or Competitive Disadvantage?
05/06/2016
David Parker, PhD
Larry Blandford, PharmD—Column Editor
We are pleased to present the second installment in our recurring column, Pharma Insights. This month we take a look at an interesting twist in how the use of complementary and companion diagnostics is playing out in...
We are pleased to present the second installment in our recurring column, Pharma Insights. This month we take a look at an interesting twist in how the use of complementary and companion diagnostics is playing out in...
We are...
05/06/2016
Journal of Clinical Pathways

Advertisement

Clinical Pathways GPS
Hitting Each Component of the Triple Aim Along the Clinical Pathway
05/06/2016
Richard G Stefanacci, DO, MGH, MBA, AGSF, CMD—Column Editor
Scott Guerin, PhD
Seth Gordon, MBA
The concept of the Triple Aim—improving the experience of care, reducing the costs of care, and improving the health of populations—is increasingly becoming important to drug manufacturers, who must demonstrate how...
The concept of the Triple Aim—improving the experience of care, reducing the costs of care, and improving the health of populations—is increasingly becoming important to drug manufacturers, who must demonstrate how...
The...
05/06/2016
Journal of Clinical Pathways
Editor's Page
For Buy-In of the Clinical Pathways Concept, Transparency Is Key
05/06/2016
Winston Wong, PharmD, Editor-in-Chief
Essential to the success of clinical pathways is transparency of the development process. This includes transparency regarding the clinical evidence reviewed, the economic evaluations made, and the process by which...
Essential to the success of clinical pathways is transparency of the development process. This includes transparency regarding the clinical evidence reviewed, the economic evaluations made, and the process by which...
...
05/06/2016
Journal of Clinical Pathways

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

JCP May/June 2024 Issue

Current Issue

June 2024
Volume 10
Issue 3
Current Issue
Issue Archive

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Special Reports

JCP Special Report
Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group
05/20/2022
Winston Wong, PharmD
Gordon Kuntz
Robin T Zon, MD, FACP, FASCO
2021 Care Pathways Working Group
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways...
05/20/2022
Journal of Clinical Pathways
Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma
Special Report
Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma
01/14/2021
01/14/2021
Journal of Clinical Pathways

Advertisement

Advertisement

Advertisement

Advertisement

Subscribe

Journal of Clinical Pathways Newsletter

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Privacy Policy Terms of Use